Skip to main content

LUMICKS enters collaboration with LAVA Therapeutics to characterize its tumor-specific γδ T-cell engagers

Amsterdam, the Netherlands – December 4, 2020 – In their quest of creating safe and effective immunotherapy cancer treatments, LUMICKS and LAVA Therapeutics joined forces. The partnership aims to evaluate the efficacy of various tumor-specific γδ T-cell engagers based on the resulting binding strengths (cell avidity) between T cells and tumors, measured with LUMICKS newly installed z-Movi® Cell Avidity Analyzer.

LAVA Therapeutics develops off-the-shelf bispecific antibodies engineered to simultaneously bind Vγ9Vδ2 T cells and tumor cells to activate tumor-cell killing. The first two γδ T-cell engagers are expected to enter the clinic in 2021.

The company will use the z-Movi® to evaluate select Vγ9Vδ2 T-cell engagers for intercellular binding characteristics in relation to their potential to activate Vγ9Vδ2 T cell-induced tumor killing. Comparison of avidities will provide insights that contribute to the development of future tumor-specific Vγ9Vδ2 T cell engagers.

We’re thrilled to join forces with LAVA Therapeutics, providing them with an effective tool to better understand characteristics of different γδ T-cell engagers and facilitate selection of top candidates for future clinical trials,” said Zhong Yu, senior global product manager at LUMICKS. “Measurements with the z-Movi® offer an unprecedented approach to study intercellular interactions, which are predictive of T-cell efficacy, and accelerate the development of tumor-specific T-cell engagers as well as other immunotherapeutic candidates.”


LUMICKS is a leading life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis, two rapidly emerging areas in biology research and immuno-oncology.  LUMICKS’ tools allow researchers to build the crucial and as yet unfinished bridge between structure and function at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms. LUMICKS’ C-Trap® Optical Tweezers – Fluorescence & Label-free Microscopy, allows scientists to analyze complex biological processes in real-time. Similarly, the z-Movi® Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

About LAVA Therapeutics

LAVA Therapeutics is developing a proprietary T-cell engager therapeutics platform for the treatment of hematological and solid cancers. The company’s first-in-class immuno-oncology approach uses bispecific antibodies that activate Vγ9Vδ2 T-cells upon binding to membrane-expressed tumor targets. LAVA was founded in 2016 based on intellectual property originating from the Amsterdam University Medical Center. The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA. For more information, please visit

For more information contact:

Kassandra Barbetsea, media contact

+31 (0) 63 482 09 48

Joshua Young, investor contact

Keely Zipp, VP Corporate Development and Portfolio Strategy at LAVA Therapeutics BV


Close Menu

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:


Download our Cell Therapy (CAR-T, TCR, NK) applications deck